Focused On-demand Library for Bone morphogenetic protein receptor type-1A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Activin receptor-like kinase 3; Serine/threonine-protein kinase receptor R5

Alternative UPACC:

P36894; A8K6U9; Q8NEN8


The Bone morphogenetic protein receptor type-1A (BMPR-1A), also known as Activin receptor-like kinase 3 and Serine/threonine-protein kinase receptor R5, plays a pivotal role in cellular processes. It forms a receptor complex upon ligand binding, activating SMAD transcriptional regulators through phosphorylation. This receptor is crucial for BMP2, BMP4, GDF5, and GDF6 signaling, influencing chondrocyte differentiation, adipogenesis, and potentially HAMP expression.

Therapeutic significance:

BMPR-1A's involvement in Juvenile polyposis syndrome and Mixed hereditary polyposis syndrome 2, diseases characterized by gastrointestinal polyps and an increased cancer risk, underscores its therapeutic potential. Targeting BMPR-1A could lead to innovative treatments for these conditions, highlighting the importance of understanding its biological functions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.